Synergistic and antagonistic interactions between docetaxel and interferon-β on growth of human breast cancer cells in vitro

International Journal of Oncology

Volumn 9, Issue 4, 1996, Pages 625-628

  Hübner, Brigitte ^a   Eckert, Klaus ^a   Maurer, H Rainer ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

docetaxel (Taxotere ); human breast cancer cell lines MCF 7 and MDA MB231; interferon

Indexed keywords

BETA INTERFERON; DOCETAXEL; ESTROGEN RECEPTOR; INTERFERON BETA SERINE; RECOMBINANT BETA INTERFERON;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0029793292     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, von Hoff DD: Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3: 121-124, 1992.
2. Riou JF, Naudin A, Lavelle F: Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187: 164-170, 1992.
3. Manfredi JJ, Horwitz SB: Taxol: An antimitotic agent with a new mechanism of action. Pharmac Ther 25: 83-125, 1994.
4. Yeh YA, Olah E, Wendel J, Sledge GW Jr. Weber G: Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule-dependence. Life Sci 54: 431-435, 1994.
5. Rowinsky ER, Citardi MJ, Noe DA, Donehower RC: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727-733, 1993.
6. Sen S, Zocchetti A, Beccaglia P, Balconi G, Erba E, Incalci MD: Heterogenous interaction of interferon-beta and taxol in human ovarian cancer cells in vitro. Eur J Cancer 30A: 892-893, 1994.
7. Marth C, Mayer I, Bock G, Gastl G, Huber Ch Flener R, Daxenbichler G: In: The Interferon System. Dianzani F, Lossi GB (eds.), Raven Press, New York pp367-385, 1985.
8. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473-3486, 1990.
9. Garbe C, Krasagakis K, Zouboulis CC, Krüger S, Waibel M, Kreuser ED, Stadler R, Orfanos CE: Kombination von Interferon-α mit Zytostatika: erfolgversprechender Therapieansatz beim metastasierendem Melanom. Hautarzt 43:4-10, 1992.
10. Ito M, Hayashi Y, Tanabe F, Shigeta S, Kawade Y: Synergistic antiproliferative effect of Interferon β in combination with bleomycin or neocarzinostatin on HeLa cells in culture: additive effect when combined with Adriamycin or mitomycin. J Interferon Res 7:419-427, 1987.
11. Ono M, Tanaka N, Orita K: Positive interactions between Interferon and cepharanthin against human cancer cells in vitro and in vivo. Cancer Chemother Pharmacol 35: 10-16, 1994.
12. Otto AM: Combinations of interferon with platinum complexes synergistic and antagonistic effects on growth inhibition of MCF-7 and MDA-MB231 cells. J Cancer Res Clin Oncol 120: 286-292, 1994.
13. Ravdin PM, Valero V: Review of docetaxel (Taxotere®), a highly active new agent for the treatment of breast cancer. Semin Oncol 22: 17-21, 1995.
14. van Oosterom AT, Schrijvers D: Docetaxel (Taxotere®), a review of preclinical and clinical experience: clinical experience. Anticancer Drugs 6: 356-368, 1995.
15. Nethersell A, Smedley H, Katrak M, Wheeler T, Sikora K: Recombinant interferon in advanced breast cancer. Br J Cancer 49: 615-619, 1985.
16. Skehan P, Storeng R, Scudiero D, Mouks A, McMahon J, Visczica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
17. Hübner B, Eckert K, Garbe C, Maurer HR: Synergistic interactions between interferon-β and carboplatin on SK-Mel28 human melanoma cell growth inhibition in vitro. J Cancer Res Clin Oncol 121: 84-88, 1995.
18. Berenbaum MC: What is synergy? Pharmacol Rev 41: 93-141, 1989.
19. Hassan HT, Maurer HR: Synergism between interferon-alpha and carboplatin in inhibiting K562 human myeloid leukemia clonogenic cells: new potential therapeutic development. Leuk Res 16:419-420, 1992.
20. Garbin F, Eckert K, Maurer HR: Evaluation of the MTT and SRB assays for testing LAK cell-mediated growth inhibition of various adherent and non-adherent tumor target cells. J Immun Methods 170: 269-271, 1994.
21. Perez RP, Godwin AK, Handel LM, Hamilton TC: A comparison of clonogenic, microtetrazolium and sulforhodamine B assay for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 3: 395-401, 1993.
22. Hahn SM, Liebmann MD, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufmann D: Taxol in combination with doxorubicin or etoposide: possible antagonism in vitro. Cancer 72: 2705-2711, 1993.
23. Gresser I, Tovey M: Antitumor effects of interferon. Biochim Biopys Acta 516: 231-247, 1978.
24. Gresser I, Maury C, Brouty-Boy D: On the mechanism of the antitumor effect of interferon in'mice. Nature 239: 167-168, 1972.
25. Chatterjee S, Cheung HC, Hunter E: Interferon inhibits Sendai virus-induced cell fusion: an effect on cell membrane fluidity. Proc Natl Acad Sci USA 79: 835-839, 1982.
26. Attalah AM, Needy CF, Noguchi-CD, Elisberg BL: Enhancement of carcinoembryonic antigen expression by interferon. Int J Cancer 24:49-52, 1979.
27. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW: Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. J Natl Cancer Inst 84: 1185-1190, 1992.
28. Sica G, Natoli V, Stella C, Bianco S: Effect of natural betaInterferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 60: 2419-2423, 1987.
29. van den Berg HW, Laehey WJ, Lynch M, Clarke R, Nelson J: Recombinant human interferon alpha increases estrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the antiproliferative effects of tamoxifen. Br J Cancer 55: 255-257, 1987.
30. Iacobelli S, Natoli C, Arno E, Sbarigia G, Gaggini C: Antiestrogenic action of interferons in human breast cancer cells. Anticancer Res 6: 1391-1394, 1986.
31. Goldstein D, Bushmeyer SM, Wilt PL, Jordan VC, Borden EC: Effects of type I and II interferons on cultured human breast cells: Interaction with estrogen receptors and with tamoxifen. Cancer Res 49: 2698-2702, 1989.